Business Wire

PHILIP-MORRIS-INTL

21.5.2019 20:46:07 CEST | Business Wire | Press release

Share
Philip Morris International Strengthens Organizational Capabilities to Realize Its Vision for a Smoke-Free Future

Philip Morris International Inc. (PMI) (NYSE:PM) today announced leadership moves to accelerate the realization of its vision of a smoke-free future and further enhance business growth. The company has created the following new roles: Chief Consumer Officer (CCO), Chief Life Sciences Officer (CLSO), Chief Product Officer (CPO) and Chief New Ventures Officer (CNVO).

“Since the launch of our smoke-free product, IQOS , in 2014, we have made enormous progress both in terms of organizational capabilities, know-how and in our business results. With IQOS commercialized in 47 markets today, we are extremely proud of what has been achieved to date, including two recent milestones: realizing 10 million users and the U.S. FDA authorization to commercialize this smoke-free alternative in the U.S.,” said André Calantzopoulos, PMI’s Chief Executive Officer. “To accelerate, we must further enhance our ability to stay at the forefront of technology, science and consumer centricity.”

All four executive positions will report to Mr. Calantzopoulos as part of PMI’s Senior Management Team (SMT). Three of the four are new hires who will replace the current role of President Science & Innovation, currently held by Mirek Zielinski, who will assume the new role of Chief New Ventures Officer.

The role of CCO will be filled by Stefano Volpetti, an expert marketer in end-to-end brand building with more than two decades of international experience working across different markets in a variety of roles. He will be responsible for grouping all consumer-facing experiences across the consumer journey—connecting with legal age smokers to drive change—from trends and insights, product and brand portfolio architecture, and consumer communications, to channel strategy.

Stepping into the role of CLSO will be Dr. John O’Mullane, a broad integrative thinker who has led innovation and R&D across all of the significant consumer healthcare categories. He will build upon PMI’s unique scientific capabilities in RRPs and outline the company’s scientific strategy for new products and services that go beyond tobacco and nicotine. He will combine scientific excellence with commercial rigor to elevate the business transformation.

The CPO role has been filled by an experienced leader from the electronics industry and will be announced in the forthcoming weeks. The CPO will be accountable for the development and acceleration of the company’s innovative smoke-free product pipeline, related technologies and electronic devices manufacturing.

“It is both humbling and reassuring that we are able to attract senior executives of such deep experience, credibility and expertise,” said Charles Bendotti, Senior Vice President People & Culture, PMI. “We look forward to their contributions in accelerating business success and achieving our vision.”

For more on these and other aspects of PMI’s game-changing transformation, visit: www.pmi.com .

About Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of March 31, 2019, PMI estimates that approximately 7.3 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, which is currently available for sale in 47 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .

Contact:

Corey Henry / David Fraser Philip Morris International Media Office T. + 1 202-609-7296 / +41 79 843 8603 E. Corey.Henry@pmi.com / David.Fraser@pmi.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Allianz Delivers Record Nine-month Result of 14.1 Billion Euros and Raises 2026 Outlook12.11.2026 07:06:00 CET | Press release

3Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111915059/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 44.4 billion euros, an internal growth of 3.0 percent1. Excellent contribution from Asset Management and good internal growth in Property-Casualty. Operating profit rises 6.2 percent to 4.7 billion euros, driven by an outstanding result from the Asset Management segment, attributable to higher business volume and margins, and a strong contribution from Life/Health. Shareholders’ core net income increases 1.2 percent to 2.9 billion euros. Adjusted for offsetting measures following the sale of the stake in our Indian JVs, underlying growth is 3 percent. 9M 2026 Total business volume at 143.0 billion euros, an internal growth of 3.8 percent 1 , driven by excellent growth in Asset Management and good internal growth in Property-Casualty. Operating profit rises 7.8 percent to 14.1 bil

LTM Brings AI-Powered Quantum Error Mitigation to IBM Quantum Functions Catalog12.11.2026 06:30:00 CET | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced that AI-QEM, its proprietary AI-powered Quantum Error Mitigation capability, is now available in the IBM Quantum Functions Catalog. With this milestone, LTM becomes the first Global Systems Integrator (GSI) worldwide to publish a function in the catalog. The IBM Quantum Functions Catalog is an ecosystem of partner-built quantum software services that simplify quantum workflows and enable researchers and enterprises to run quantum experiments more efficiently for algorithm development and application prototyping. AI-QEM is available as a circuit function, allowing users of eligible IBM Quantum access plans to apply LTM's error mitigation capability directly within their Qiskit workflows. Quantum computers are inherently susceptible to noise and errors that can impact computational outcomes. While conventional error mitigation techniques often require additional circuit executions, quantum processing

Access Advance Announces New Effective Discount Rates for Its Multi-Codec Bridging Agreement, Starting on January 1, 202711.11.2026 20:18:00 CET | Press release

Access Advance LLC today announced that the Licensors of the HEVC Advance and VVC Advance Patent Pools have independently approved a two-step, phased reduction in the effective royalty discount available under the Multi-Codec Bridging Agreement (MCBA) for Licensees of both pools who sign the MCBA on or after January 1, 2027. Licensees that join both the HEVC Advance and VVC Advance Patent Pools and execute the MCBA on or before December 31, 2026, will secure the current MCBA rates, resulting in an effective discount of up to 50%. Licensees that sign on or after January 1, 2027 will receive a reduced discount as further described below. The MCBA is an administrative agreement, not a separate license, that lets Licensees of both HEVC Advance and VVC Advance Patent Pools pay a single, reduced royalty rate for products that include both HEVC and VVC codecs. Today the MCBA rate for a dual-codec product is the same as the VVC Advance single codec product rate; up to 50% of what a Licensee wo

Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press release

Angel Elevates the Orthodontic Specialty by Focusing on Complex-Case Solutions Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bind

Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press release

Partnerships span drug discovery, clinical research, preventive and reproductive health Launch of an AI Clinician Framework and a Trusted Research Environment for health and genomic data Four whitepapers address genomics, therapeutics, fertility and wearable technologies New programmes support health innovators and entrepreneurs More than 17,300 visitors from 85 countries, with 130 speakers across 45 sessions Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gath

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye